Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue

Vascular permeability factor (VPF, also known as vascular endothelial growth factor or VEGF), is a potent microvascular permeability enhancing cytokine and a selective mitogen for endothelial cells. It has been implicated in tumor angiogenesis and ascites fluid accumulation. Since development of the destructive synovial pannus in rheumatoid arthritis (RA) is associated with changes in vascular permeability (synovial fluid accumulation), synovial cell hyperplasia, and angiogenesis, we examined synovial fluids (SFs) and joint tissue for the expression and local accumulation of VPF/VEGF. VPF/VEGF was detected in all of 21 synovial fluids examined and when measured by an immunofluorimetric assay, ranged from 6.9 to 180.5 pM. These levels are biologically significant, since < 1 pM VPF/VEGF can elicit responses from its target cells, endothelial cells. Levels of VPF/VEGF were highest in rheumatoid arthritis fluids (n = 10), with a mean value (+/- SEM) of 59.1 +/- 18.0 pM, vs. 21.4 +/- 2.3 pM for 11 SFs from patients with other forms of arthritis (p = 0.042). In situ hybridization studies that were performed on joint tissues from patients with active RA revealed that synovial lining macrophages strongly expressed VPF/VEGF mRNA, and that microvascular endothelial cells of nearby blood vessels strongly expressed mRNA for the VPF/VEGF receptors, flt-1 and KDR. Immunohistochemistry performed on inflamed rheumatoid synovial tissue revealed that the VPF/VEGF peptide was localized to macrophages within inflamed synovium, as well as to microvascular endothelium, its putative target in the tissue. Together, these findings indicate that VPF/VEGF may have an important role in the pathogenesis of RA.

[1]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[2]  J. Weinberg,et al.  Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[3]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[4]  E. Manseau,et al.  Vascular permeability factor mRNA and protein expression in human kidney. , 1992, Kidney international.

[5]  E. Haber,et al.  Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. , 1983, Science.

[6]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[7]  Harold E. Dvorak,et al.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.

[8]  A. Kang,et al.  Autoimmunity to type II collagen an experimental model of arthritis , 1977, The Journal of experimental medicine.

[9]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. , 1993, Cancer research.

[10]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[11]  D. Senger,et al.  Development of time-resolved immunofluorometric assay of vascular permeability factor. , 1992, Clinical chemistry.

[12]  T. Pincus,et al.  Active and latent forms of transforming growth factor beta activity in synovial effusions , 1989, The Journal of experimental medicine.

[13]  E. Manseau,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.

[14]  G. Nuki,et al.  Tumour necrosis factor in synovial exudates. , 1988, Annals of the rheumatic diseases.

[15]  H. Dvorak,et al.  Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. , 1993, Archives of biochemistry and biophysics.

[16]  K. Gatter,et al.  KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. , 1989, Journal of clinical pathology.

[17]  E. Remmers,et al.  Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. , 1993, The Journal of clinical investigation.

[18]  R. Strieter,et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.

[19]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[20]  J. Case,et al.  Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints , 1990, The Journal of cell biology.

[21]  N. Ferrara,et al.  Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.

[22]  D. Connolly,et al.  Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. , 1990, Cancer research.

[23]  P. Colville-Nash,et al.  Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. , 1992, Annals of the rheumatic diseases.

[24]  H. Dvorak,et al.  Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[25]  L. Williams,et al.  Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Dvorak,et al.  Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. , 1991, The American journal of pathology.

[27]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. , 1992, Molecular biology of the cell.

[28]  T. Pincus,et al.  In vitro rheumatoid factor synthesis in patients taking second-line drugs for rheumatoid arthritis. Independent associations with disease activity. , 1988, Arthritis and rheumatism.

[29]  S. Wahl,et al.  Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium. , 1990, Journal of immunology.

[30]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[31]  C. Dunwiddie,et al.  Pathways of coagulation activation in situ in rheumatoid synovial tissue. , 1992, Clinical immunology and immunopathology.

[32]  E. Brahn,et al.  Angiogenesis inhibition suppresses collagen arthritis , 1992, The Journal of experimental medicine.